-
Mashup Score: 0Annals of Internal Medicine - 9 hour(s) ago
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t sign in? Forgot your username?
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Background: In the United States, older adults have elevated prevalence of latent tuberculosis infection (LTBI) and incidence of tuberculosis (TB). Objective: To estimate the health benefits and cost-effectiveness of LTBI testing and treatment among the Medicare-eligible population. Design: Model-based cost-effectiveness analysis. Data Sources: Nationally representative surveys and published evidence. Target Population: Medicare-eligible persons aged 65 years or older with at least 1 of 15 factors associated with elevated TB risk, as identified by guidelines from the U.S. Preventive Services Task Force (USPSTF) and other organizations. Time Horizon: Lifetime. Perspective: Societal. Intervention: One-time offer of LTBI testing and treatment versus no intervention. Outcome Measures: Lifetime TB cases and deaths averted, quality-adjusted life-years (QALYs) gained, costs, and incremental cost-effectiveness ratios (ICERs). Results of Base-Case Analysis: In 2022, there were an estimated 29.9
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet-
New today: Testing and treating Medicare-eligible persons at risk or latent #tuberculosis infection could lead to substantial reductions in TB and TB-related mortality, particularly among 65-year-olds newly eligible for Medicare. https://t.co/3Kff2iBv5N @HarvardChanSPH @CDCgov… https://t.co/QUkat09imZ https://t.co/fK2O2XLZAW
-
-
Mashup Score: 5Annals of Internal Medicine - 1 day(s) ago
Anders Hviid, DrMedSci, J ø rgen Vinsl ø v Hansen, PhD, Morten Frisch, DrMedSci, and Mads Melbye, DrMedSci Amir Qaseem, MD, PhD, MHA, Timothy J. Wilt, MD, MPH, Robert M. McLean, MD, and Mary Ann Forciea, MD, for the Clinical Guidelines Committee of the American College of Physicians* Amir Qaseem, MD, PhD, MHA, Lauri A. Hicks, DO, Itziar Etxeandia-Ikobaltzeta, PharmD, Tatyana Shamliyan, MD, MS, and Thomas G. Cooney, MD, for the Clinical Guidelines Committee of the American College of Physicia ns
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet-
Authors provided insight into 3 breaking news research articles during a live scientific plenary session at #IM2024. Read about time-restricted eating, next-gen #antibiotics, and @ACPIMPhysicians guideline on Type 2 #diabetes https://t.co/MQNtLKA6hO. @NMaruthur @SameerKadri12 https://t.co/9lyefJA1Gs
-
-
Mashup Score: 0A Calling No Longer? When Medicine Is Redefined as a Job | Annals of Internal Medicine - 2 day(s) ago
Is medicine a calling or a job? The authors of this article see benefit in recognizing that medicine can be a personal calling as long as we also recognize that the field’s evolving nature requires…
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Description: The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DOD) updated the 2019 joint clinical practice guideline (CPG) for assessing and managing patients who are at risk for suicide. This synopsis provides primary care physicians with a summary of the updated 2024 recommendations regarding evaluation and management of military members and veterans at risk for suicide. Methods: In 2023, the VA/DOD Evidence-Based Practice Work Group convened to develop a joint VA/DOD guideline, including clinical stakeholders, which conformed to the National Academy of Medicine’s tenets for trustworthy CPGs. The Work Group drafted 12 key questions, reviewed systematically identified literature (1 April 2018 to 15 March 2023), evaluated the evidence, created algorithms, and advanced 24 recommendations in accordance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: Despite insufficient evidence to recommend for or a
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 11
Description: Artificial intelligence (AI) has been defined by the High-Level Expert Group on AI of the European Commission as “systems that display intelligent behaviour by analysing their environment and taking actions—with some degree of autonomy—to achieve specific goals.” Artificial intelligence has the potential to support guideline planning, development and adaptation, reporting, implementation, impact evaluation, certification, and appraisal of recommendations, which we will refer to as “guideline enterprise.” Considering this potential, as well as the lack of guidance for the use of AI in guidelines, the Guidelines International Network (GIN) proposes a set of principles for the development and use of AI tools or processes to support the health guideline enterprise. Methods: A GIN working group on AI developed these principles, informed by the results of a scoping review and practical examples, through iterative discussion. Recommendations: Eight principles were identified to a
Source: www.acpjournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t sign in? Forgot your username? The mission of the Annals of Internal Medicine: Clinical Cases (AIMCC) is to promote excellence in critical thinking around prevention, diagnosis, and management of challenging clinical situations and awareness of new or unique clinical entities by disseminating rigorously peer-reviewed reports of real clinical cases
Source: www.acpjournals.orgCategories: General Medicine News, Cardiac SurgeryTweet
-
Mashup Score: 12
Background: Various treatments for preventing episodic migraine are available. Purpose: To evaluate the comparative effectiveness and harms of pharmacologic prevention of episodic migraine, focusing on treatments already determined to be superior to placebo. Data Sources: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from inception until April 2024. Study Selection: Randomized trials evaluating selected efficacious pharmacologic treatments in adults with episodic migraine. Selection was done independently by 2 reviewers. Data Extraction: Data were extracted by 1 reviewer and checked by a second. Risk of bias and certainty of the evidence were assessed using the Cochrane Risk of Bias tool and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, respectively. Data Synthesis: Sixty-one studies (20 680 patients) evaluating 16 treatments were included. Nineteen studies had low risk of bias. All selected treatments were deemed effi
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6
Description: The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DOD) updated the 2019 joint clinical practice guideline (CPG) for assessing and managing patients who are at risk for suicide. This synopsis provides primary care physicians with a summary of the updated 2024 recommendations regarding evaluation and management of military members and veterans at risk for suicide. Methods: In 2023, the VA/DOD Evidence-Based Practice Work Group convened to develop a joint VA/DOD guideline, including clinical stakeholders, which conformed to the National Academy of Medicine’s tenets for trustworthy CPGs. The Work Group drafted 12 key questions, reviewed systematically identified literature (1 April 2018 to 15 March 2023), evaluated the evidence, created algorithms, and advanced 24 recommendations in accordance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: Despite insufficient evidence to recommend for or a
Source: www.acpjournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 13
Background: Monovalent COVID-19 vaccines targeting the XBB.1.5 Omicron variant were introduced in September 2023. In the absence of randomized controlled trials demonstrating their efficacy, information on real-world vaccine effectiveness (VE) is needed. Objective: To determine XBB.1.5 COVID-19 VE and the extent to which it declines over time. Design: Target trial emulation. Setting: U.S. Veterans Health Administration. Participants: Eligible XBB.1.5 vaccine recipients were matched 1:1 to unvaccinated persons in 7 sequential biweekly trials with enrollment from 2 October 2023 through 3 January 2024. Intervention: XBB.1.5 COVID-19 vaccination versus no XBB.1.5 vaccination. Measurements: Outcomes were ascertained through 10 May 2024 and included any positive result on a SARS-CoV-2 test from day 10 after the matched index date, subsequent hospitalization within 1 day before or 10 days after the positive result, or death within 30 days after the positive result. Vaccine effectiveness was e
Source: www.acpjournals.orgCategories: General Medicine News, Infectious DiseaseTweet
Annals of Internal Medicine’s specialty collections include research, reviews, and expert opinion on topics ranging from cardiology to prevention efforts. View our specialty collections here: https://t.co/fld4TY39IM https://t.co/iqqN5WyhjF